Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML - Trial NCT05463640
Access comprehensive clinical trial information for NCT05463640 through Pure Global AI's free database. This Phase 1 trial is sponsored by Zhejiang University and is currently Not yet recruiting. The study focuses on AML. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Zhejiang University
Timeline & Enrollment
Phase 1
Aug 02, 2022
Aug 02, 2025
Primary Outcome
Changes in cytokine level after ADGRE2 CAR-T infusion.,The change characteristics of chimeric antigen receptor(CAR)-T cell number and copy number in patients after infusion.
Summary
This is an open label, phase I study to assess the safety and efficacy of ADGRE2 CAR-T in
 patients with relapsed and refractory acute myeloid leukemia
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05463640
Non-Device Trial